Scientists have developed a tool that can predict how bowel cancer adapts to treatment—helping researchers to design new ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

New research shows that treatment timing is key when it comes to deciding between immunotherapy and chemoimmunotherapy for ...

Justin Taylor, M.D., a physician-scientist at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller ...

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of ...

The venom of a common species of Amazonian scorpion may give rise to a potential drug for treating a cancer that is one of ...

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve ...

A chemotherapy-free approach for some patients suffering from leukaemia could lead to better outcomes, scientists behind a ...

ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.

The exercise prescriptions also prevented other new cancers, like breast and prostate cancer. Many included just three to ...

To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...